Quanterix (QTRX) 10-Q 9 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 01, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity Registrant Name	Quanterix Corp
Entity File Number	001-38319
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-8957988
Entity Address, Address Line One	900 Middlesex Turnpike
Entity Address, City or Town	Billerica
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01821
City Area Code	617
Local Phone Number	301-9400
Title of 12(g) Security	Common Stock, $0.001 par value per share
Trading Symbol	QTRX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		37,054,705
Entity Central Index Key	0001503274
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 343,743	$ 396,465
Accounts receivable (less allowance for credit losses of $521 and $419 as of September 30, 2022 and December 31, 2021, respectively)	18,330	23,786
Inventory	18,236	22,190
Prepaid expenses and other current assets	6,475	6,514
Total current assets	386,784	448,955
Restricted cash	2,596	2,577
Property and equipment, net	21,441	17,960
Intangible assets, net	7,511	10,534
Goodwill		9,632
Right-of-use assets	27,165	11,491
Other non-current assets	1,200	378
Total assets	446,697	501,527
Current liabilities:
Accounts payable	2,106	9,209
Accrued compensation and benefits	10,503	13,252
Other accrued expenses	5,951	6,486
Deferred revenue	8,976	6,361
Short term lease liabilities	767	1,428
Other current liabilities	268	241
Total current liabilities	28,571	36,977
Deferred revenue, net of current portion	1,591	1,099
Long term lease liabilities	42,196	20,464
Other non-current liabilities	1,570	2,035
Total Liabilities	73,928	60,575
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock, $0.001 par value: Authorized shares: 120,000,000 at September 30, 2022 and December 31, 2021, respectively; Issued and outstanding: 37,093,601 shares and 36,768,035 shares at September 30, 2022 and December 31, 2021, respectively	37	37
Additional paid-in capital	759,312	745,936
Accumulated other comprehensive (loss) income	(2,999)	441
Accumulated deficit	(383,581)	(305,462)
Total stockholders' equity	372,769	440,952
Total liabilities and stockholders' equity	$ 446,697	$ 501,527

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Condensed Consolidated Balance Sheets
Accounts receivable, reserve for doubtful accounts	$ 521	$ 419
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized shares	120,000,000	120,000,000
Common stock, shares issued	37,093,601	36,768,035
Common stock, shares outstanding	37,093,601	36,768,035

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenue	$ 26,646	$ 27,689	$ 79,698	$ 80,269
Costs of goods sold:
Total costs of goods sold and services	15,702	12,445	45,484	34,802
Gross profit	10,944	15,244	34,214	45,467
Operating expenses:
Research and development	6,631	6,807	20,290	20,244
Selling, general and administrative	19,966	23,670	72,723	63,913
Other lease costs	609		609
Restructuring	3,426		3,426
Goodwill impairment	8,220		8,220
Impairment of long-lived assets	8,695		8,695
Total operating expenses	47,547	30,477	113,963	84,157
Loss from operations	(36,603)	(15,233)	(79,749)	(38,690)
Interest income (expense), net	1,712	(90)	2,316	(418)
Other (expense) income, net	(101)	(305)	(676)	1,478
Loss before income taxes	(34,992)	(15,628)	(78,109)	(37,630)
Income tax provision	72	33	10	32
Net loss	$ (35,064)	$ (15,661)	$ (78,119)	$ (37,662)
Net loss per share, basic (in dollars per share)	$ (0.95)	$ (0.43)	$ (2.12)	$ (1.05)
Net loss per share, diluted (in dollars per share)	$ (0.95)	$ (0.43)	$ (2.12)	$ (1.05)
Weighted-average common shares outstanding, basic (in shares)	37,004,596	36,518,177	36,926,549	35,774,455
Weighted-average common shares outstanding, diluted (in shares)	37,004,596	36,518,177	36,926,549	35,774,455
Product revenue
Total revenue	$ 17,693	$ 20,662	$ 53,134	$ 57,586
Costs of goods sold:
Total costs of goods sold and services	10,511	8,639	31,178	24,233
Service and other revenue
Total revenue	8,370	5,898	25,728	17,955
Costs of goods sold:
Total costs of goods sold and services	5,191	3,806	14,306	10,569
Collaboration and license revenue
Total revenue	301	120	479	486
Grant revenue
Total revenue	$ 282	$ 1,009	$ 357	$ 4,242

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Condensed Consolidated Statements of Comprehensive Loss
Net loss	$ (35,064)	$ (15,661)	$ (78,119)	$ (37,662)
Other comprehensive loss:
Cumulative translation adjustment	(796)	(527)	(3,440)	(1,383)
Total other comprehensive (loss) income	(796)	(527)	(3,440)	(1,383)
Comprehensive loss	$ (35,860)	$ (16,188)	$ (81,559)	$ (39,045)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (78,119)	$ (37,662)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	4,186	3,566
Credit loss expense on accounts receivable	102	286
Inventory step-up amortization		275
Non-cash operating lease expense	1,099	364
Stock-based compensation expense	11,779	11,044
Goodwill impairment	8,220
Impairment of long-lived assets	8,695
Other non-cash items	39	65
Changes in operating assets and liabilities:
Accounts receivable	5,045	(1,556)
Inventory	3,919	(8,431)
Prepaid expenses and other assets	(262)	(1,395)
Other non-current assets	(859)	(3)
Accounts payable	(7,085)	(972)
Accrued compensation and benefits, other accrued expenses and other current liabilities	(3,021)	(2,860)
Deferred revenue	3,108	674
Operating lease liabilities	(1,156)	(902)
Other non-current liabilities	128	(108)
Net cash used in operating activities	(44,182)	(37,615)
Investing activities
Purchases of property and equipment	(10,131)	(11,163)
Proceeds from RADx grant on assets purchased	520	7,019
Net cash used in investing activities	(9,611)	(4,144)
Financing activities
Proceeds from stock options exercised	716	6,607
Sale of common stock in underwritten public offering, net		269,718
Proceeds from ESPP purchase	881	1,065
Payments on notes payable		(5,744)
Net cash provided by financing activities	1,597	271,646
Net (decrease) increase in cash, cash equivalents and restricted cash	(52,196)	229,887
Effect of foreign currency exchange rate on cash	(507)	(66)
Cash, cash equivalents and restricted stock at beginning of period	399,042	182,584
Cash, cash equivalents and restricted stock at end of period	346,339	412,405
Supplemental disclosure of cash flow information:
Cash paid for income taxes	263	320
Noncash transactions:
Purchases of property and equipment included in accounts payable	198	$ 306
Right-of-use asset obtained in exchange for lease liabilities	$ 22,239

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Reconciliation of cash, cash equivalents, and restricted cash:
Cash and cash equivalents	$ 343,743	$ 396,465	$ 410,747
Restricted cash	2,596	2,577	1,658
Total cash, cash equivalents, and restricted cash	$ 346,339	$ 399,042	$ 412,405	$ 182,584

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common stock	Additional paid-in capital	Accumulated other comprehensive income (loss)	Accumulated deficit	Total
Beginning Balance at Dec. 31, 2020	$ 32	$ 451,433	$ 2,434	$ (247,774)	$ 206,125
Beginning balance (in shares) at Dec. 31, 2020	31,796,544
Increase (Decrease) in Stockholders' Equity
Exercised warrants (in shares)	7,347
Exercised stock options	$ 1	6,606			6,607
Exercised stock options (in shares)	455,476
Restricted units converted (in shares)	175,526
ESPP stock purchase		1,065			1,065
ESPP stock purchase (in shares)	29,037
Issuance of common stock (in shares)	3,060
Sale of common stock in underwritten public offering, net	$ 4	269,714			269,718
Sale of common stock in underwritten public offering, net (in shares)	4,107,142
Stock-based compensation expense		11,044			11,044
Cumulative translation adjustment			(1,383)		(1,383)
Net loss				(37,662)	(37,662)
Ending Balance at Sep. 30, 2021	$ 37	739,862	1,051	(285,436)	455,514
Ending Balance (in shares) at Sep. 30, 2021	36,574,132
Beginning Balance at Dec. 31, 2020	$ 32	451,433	2,434	(247,774)	206,125
Beginning balance (in shares) at Dec. 31, 2020	31,796,544
Increase (Decrease) in Stockholders' Equity
Cumulative translation adjustment			(1,993)
Ending Balance at Dec. 31, 2021	$ 37	745,936	441	(305,462)	440,952
Ending Balance (in shares) at Dec. 31, 2021	36,768,035
Beginning Balance at Jun. 30, 2021	$ 37	734,170	1,578	(269,775)	466,010
Beginning balance (in shares) at Jun. 30, 2021	36,454,369
Increase (Decrease) in Stockholders' Equity
Exercised stock options		1,138			1,138
Exercised stock options (in shares)	63,097
Restricted units converted (in shares)	43,902
ESPP stock purchase		546			546
ESPP stock purchase (in shares)	11,812
Issuance of common stock (in shares)	952
Stock-based compensation expense		4,008			4,008
Cumulative translation adjustment			(527)		(527)
Net loss				(15,661)	(15,661)
Ending Balance at Sep. 30, 2021	$ 37	739,862	1,051	(285,436)	455,514
Ending Balance (in shares) at Sep. 30, 2021	36,574,132
Increase (Decrease) in Stockholders' Equity
Accumulated other comprehensive income					441
Beginning Balance at Dec. 31, 2021	$ 37	745,936	441	(305,462)	440,952
Beginning balance (in shares) at Dec. 31, 2021	36,768,035
Increase (Decrease) in Stockholders' Equity
Exercised stock options		716			716
Exercised stock options (in shares)	117,986
Restricted units converted (in shares)	144,553
ESPP stock purchase		881			881
ESPP stock purchase (in shares)	57,485
Issuance of common stock (in shares)	5,542
Stock-based compensation expense		11,779			11,779
Cumulative translation adjustment			(3,440)		(3,440)
Net loss				(78,119)	(78,119)
Ending Balance at Sep. 30, 2022	$ 37	759,312	(2,999)	(383,581)	372,769
Ending Balance (in shares) at Sep. 30, 2022	37,093,601
Beginning Balance at Jun. 30, 2022	$ 37	756,139	(2,203)	(348,517)	405,456
Beginning balance (in shares) at Jun. 30, 2022	36,974,827
Increase (Decrease) in Stockholders' Equity
Exercised stock options		120			120
Exercised stock options (in shares)	33,450
Restricted units converted (in shares)	45,519
ESPP stock purchase		287			287
ESPP stock purchase (in shares)	37,036
Issuance of common stock (in shares)	2,769
Stock-based compensation expense		2,766			2,766
Cumulative translation adjustment			(796)		(796)
Net loss				(35,064)	(35,064)
Ending Balance at Sep. 30, 2022	$ 37	$ 759,312	$ (2,999)	$ (383,581)	372,769
Ending Balance (in shares) at Sep. 30, 2022	37,093,601
Increase (Decrease) in Stockholders' Equity
Accumulated other comprehensive income					$ (2,999)

Organization and operations

Organization and operations	9 Months Ended
	Sep. 30, 2022
Organization and operations
Organization and operations	1. Organization and operations ​ Quanterix Corporation (Nasdaq: QTRX) (the Company) is a life sciences company that has developed next generation, ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. The Company's platforms are based on its proprietary digital “Simoa” detection technology. The Company's Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allow researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations. These capabilities provide the Company's customers with insight into the role of protein biomarkers in human health that has not been possible with other existing technologies and enable researchers to unlock unique insights into the continuum between health and disease. The Company is currently focusing on protein detection, which it believes is an area of significant unmet need and where it has significant competitive advantages. In addition to enabling new applications and insights in protein analysis, the Company’s Simoa platforms have also demonstrated applicability across other testing applications, including detection of nucleic acids and small molecules. ​ The Company launched its first immunoassay platform, the Simoa HD-1 (HD-1), in 2014. The HD-1 is a fully automated immunoassay bead-based platform with multiplexing and custom assay capability, and related assay test kits and consumable materials. In the fourth quarter of 2017, the Company launched a second bead-based immunoassay platform (SR-X) with a more compact footprint than the HD-1 and less automation designed for lower volume requirements while still allowing multiplexing and custom assay capability. The Company initiated an early-access program for its third instrument (SP-X) on the new Simoa planar array platform in January 2019, with the full commercial launch commencing in April 2019. In July 2019, the Company launched the Simoa HD-X, an upgraded version of the HD-1 and phased out the HD-1. The HD-X has been designed to deliver significant productivity and operational efficiency improvements, as well as greater user flexibility. The Company began shipping and installing HD-X instruments at customer locations in the third quarter of 2019. The Company also performs research services on behalf of customers to apply the Simoa technology to specific customer needs. The Company's customers are primarily in the research use only market, which includes academic and governmental research institutions, the research and development laboratories of pharmaceutical manufacturers, contract research organizations, and specialty research laboratories. ​ Basis of presentation ​ The interim condensed consolidated financial statements are unaudited. The unaudited condensed consolidated financial statements reflect, in the opinion of the Company’s management, all adjustments, consisting of only normal recurring adjustments, necessary for a fair presentation of financial position, results of operations, comprehensive loss and cash flows for each period presented and have been prepared in accordance with United States generally accepted accounting principles (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022. ​ Reclassifications Certain amounts in the prior years’ consolidated financial statements have been reclassified to conform to the current year’s presentation.

Significant accounting policies

Significant accounting policies	9 Months Ended
	Sep. 30, 2022
Significant accounting policies
Significant accounting policies	2. Significant accounting policies The significant accounting policies and estimates used in the preparation of the accompanying consolidated financial statements are described in the Company’s audited consolidated financial statements for the year ended December 31, 2021, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 1, 2022. Except as noted below, there have been no material changes in the Company’s significant accounting policies during the nine months ended September 30, 2022. Goodwill Goodwill represents the excess of the cost of acquired businesses over the fair value of identifiable net assets assumed in a business combination. Goodwill is assessed for impairment at least annually, on a reporting unit basis, or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. Reporting units are one level below the business segment level but can be combined when reporting units within the same segment have similar economic characteristics. The Company operates within a single Long-lived assets The Company accounts for long-lived assets including property and equipment and long-lived amortizable intangible assets in accordance with ASC Topic No. 360, Property, Plant and Equipment, . Restructuring The Company records charges associated with approved restructuring plans to reorganize operations, to improve the efficiency of business processes, or to remove redundant headcount. Restructuring charges can include severance costs to eliminate a specific number of employees, associated legal fees and contract cancellation costs. The Company records restructuring charges when they are probable and estimable. The Company accrues for severance and other employee separation costs under these plans when employees accept the separation offers, and the amounts can be reasonably estimated. The Company implemented a restructuring plan (as defined herein) during the three months ended September 30, 2022 details of which are discussed in Note 17. Other lease costs As part of the Restructuring Plan, the Company is not utilizing the office and laboratory space leased in Bedford, Massachusetts, and is evaluating alternatives uses for the facilities, including terminating the lease or sub-leasing the facilities. Other lease costs on the consolidated statements of operations includes lease expenses and other facilities costs associated with these facilities for the periods after the determination the facilities would not be utilized.

Revenue recognition

Revenue recognition	9 Months Ended
	Sep. 30, 2022
Revenue recognition
Revenue recognition	3. Revenue recognition The Company recognizes revenue when a customer obtains control of a promised good or service. The amount of revenue recognized reflects consideration that the Company expects to be entitled to receive in exchange for these goods and services, incentives and taxes collected from customers that are subsequently remitted to governmental authorities. Customers The Company’s customers primarily consist of entities engaged in the life sciences research market that pursue the discovery and development of new drugs for a variety of neurologic, cardiovascular, oncologic and other protein biomarkers associated with diseases. The Company’s customer base includes several of the largest biopharmaceutical companies, academic research organizations and distributors who serve certain geographic markets. Product revenue The Company’s products are composed of analyzer instruments, assay kits and other consumables such as reagents. Products are sold directly to biopharmaceutical and academic research organizations or are sold through distributors in EMEA and Asia Pacific regions. The sales of instruments are generally accompanied by an initial year of implied service-type warranties and may be bundled with assays and other consumables and may also include other items such as training and installation of the instrument and/or an extended service warranty. Revenues from the sale of products are recognized at a point in time when the Company transfers control of the product to the customer, which is generally upon installation for instruments sold to direct customers, and based upon shipping terms for assay kits and other consumables. Revenue for instruments sold to distributors is generally recognized based upon shipping terms (either upon shipment or delivery). Service and other revenue Service revenues are composed of contract research services, initial implied one-year service-type warranties, extended services contracts and other services such as training. Contract research services are provided through the Company’s Accelerator Laboratory and generally consist of fixed fee contracts. Revenues from contract research services are recognized at a point in time when the Company completes and delivers its research report on each individually completed study, or over time if the contractual provisions allow for the collection of transaction consideration for costs incurred plus a reasonable margin through the period of performance of the services. Revenues from service-type warranties are recognized ratably over the contract service period. For contract research services recognized over time, the Company uses the output method to measure the progress toward the complete satisfaction of the performance obligations. Revenues from other services are immaterial. During the first quarter of 2022, the Company entered into a Master Collaboration Agreement with Eli Lilly and Company (Lilly) establishing a framework for future projects focused on the development of Simoa immunoassays (the Lilly Collaboration Agreement). The Company also entered into a Statement of Work under the Lilly Collaboration Agreement to perform assay research and development services within the field of Alzheimer’s disease. In connection with the Lilly Collaboration Agreement, the Company received a non-refundable up-front payment of $5.0 million during the first quarter of 2022, and under the Statement of Work receives $1.5 million per calendar quarter during 2022, beginning with the first quarter of 2022. The revenue will be recognized over a one-year period. ​ Concurrent with the execution of the Lilly Collaboration Agreement, the Company entered into a Technology License Agreement (the Lilly License) under which Lilly granted to the Company a non-exclusive license to Lilly’s proprietary P-tau217 antibody technology for potential near-term use in research use only products and services and future in vitro ​ The Company concluded that the Lilly Collaboration Agreement (including the Statement of Work) and the Lilly License represented a single contract with a customer and is accounting for the agreements as service revenue recognized over time as the services are delivered. The transaction price for the Lilly Collaboration Agreement is $10.9 million. Contingent amounts due to Lilly represent variable consideration payable to a customer and will be recognized as reductions to service revenue up to the amount of the transaction price recognized, when probable. The Company is utilizing an input method to measure the delivery of services by calculating costs incurred at each period end relative to total costs expected to be incurred. ​ During the three and nine months ended September 30, 2022, the Company recognized approximately $2.7 million and $8.1 million, respectively, of revenue from the Lilly Collaboration Agreement. Collaboration and license revenue The Company may enter into agreements to license the intellectual property and know-how associated with its instruments and certain antibodies in exchange for license fees and future royalties (as described below). The license agreements provide the licensee with a right to use the intellectual property with the license fee revenues recognized at a point in time as the underlying license is considered functional intellectual property. Payment terms The Company’s payment terms vary by the type and location of the customer and the products or services offered. Payment from customers is generally required in a term ranging from 30 to 45 days from date of shipment or satisfaction of the performance obligation. The Company does not provide financing arrangements to its customers. Disaggregated revenue When disaggregating revenue, the Company considered all of the economic factors that may affect its revenues. The following tables disaggregate the Company’s revenue from contracts with customers by revenue type (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022 Three Months Ended September 30, 2021 ​ North America EMEA Asia Pacific Total ​ North America EMEA Asia Pacific Total Product revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Instruments $ 2,964 ​ ​ 3,115 ​ ​ 1,684 ​ $ 7,763 ​ $ 3,492 ​ $ 1,644 ​ $ 1,338 $ 6,474 Consumable and other products ​ 6,262 ​ ​ 2,840 ​ ​ 828 ​ ​ 9,930 ​ ​ 8,915 ​ ​ 4,483 ​ ​ 790 ​ 14,188 Total $ 9,226 ​ ​ 5,955 ​ ​ 2,512 ​ $ 17,693 ​ $ 12,407 $ 6,127 $ 2,128 $ 20,662 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Service and other revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Service-type warranties $ 1,454 ​ $ 703 ​ $ 125 ​ $ 2,282 ​ $ 1,112 ​ $ 556 ​ $ 66 $ 1,734 Research services ​ 5,246 ​ ​ 305 ​ ​ 44 ​ 5,595 ​ ​ 2,998 ​ ​ 604 ​ ​ 50 ​ 3,652 Other services ​ 315 ​ ​ 142 ​ ​ 36 ​ ​ 493 ​ ​ 465 ​ ​ 47 ​ ​ — ​ 512 Total $ 7,015 ​ $ 1,150 ​ $ 205 ​ $ 8,370 ​ $ 4,575 ​ $ 1,207 ​ $ 116 ​ $ 5,898 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Collaboration and license revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Collaboration and license revenue $ 136 ​ $ 165 ​ $ — ​ $ 301 ​ $ 73 ​ $ 47 ​ $ — ​ $ 120 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2022 Nine Months Ended September 30, 2021 ​ North America EMEA Asia Pacific Total ​ North America EMEA Asia Pacific Total Product revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Instruments $ 7,602 ​ $ 7,288 ​ $ 4,699 ​ $ 19,589 ​ $ 9,370 ​ $ 6,107 ​ $ 3,796 ​ $ 19,273 Consumable and other products ​ 19,814 ​ ​ 10,854 ​ ​ 2,877 ​ ​ 33,545 ​ ​ 24,638 ​ ​ 11,227 ​ ​ 2,448 ​ ​ 38,313 Total $ 27,416 $ 18,142 $ 7,576 $ 53,134 ​ $ 34,008 $ 17,334 $ 6,244 $ 57,586 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Service and other revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Service-type warranties $ 4,057 ​ $ 2,050 ​ $ 341 ​ $ 6,448 ​ $ 3,181 ​ $ 1,452 ​ $ 179 ​ $ 4,812 Research services ​ 16,853 ​ ​ 752 ​ ​ 65 ​ 17,670 ​ ​ 9,285 ​ ​ 2,095 ​ ​ 89 ​ 11,469 Other services ​ 916 ​ ​ 590 ​ ​ 104 ​ ​ 1,610 ​ ​ 1,271 ​ ​ 403 ​ ​ — ​ ​ 1,674 Total $ 21,826 ​ $ 3,392 ​ $ 510 ​ $ 25,728 ​ $ 13,737 ​ $ 3,950 ​ $ 268 ​ $ 17,955 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Collaboration and license revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Collaboration and license revenue $ 179 ​ $ 248 ​ $ 52 ​ $ 479 ​ $ 301 ​ $ 185 ​ $ — ​ $ 486 ​ For the three and nine months ended September 30, 2022, two customers accounted for 14.1% and 11.1%, respectively, of the Company’s total revenue. At September 30, 2022, two customers individually accounted for 13.4% and 10.1% , respectively, of the Company’s gross accounts receivable. The Company’s contracts with customers may include promises to transfer multiple products and services to a customer. The Company combines any performance obligations that are immaterial with one or more other performance obligations that are material to the contract. For arrangements with multiple performance obligations, the Company allocates the contract transaction price, including discounts, to each performance obligation based on its relative standalone selling price. Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company determines standalone selling prices based on prices charged to customers in observable transactions and uses a range of amounts to estimate standalone selling prices for each performance obligation. The Company may have more than one range of standalone selling price for certain products and services based on the pricing for different customer classes. Variable consideration in the Company’s contracts primarily relates to (i) sales- and usage-based royalties related to the license of intellectual property in collaboration and license contracts and (ii) certain non-fixed fee research services contracts. Accounting Standard Codification (ASC) Topic 606, Revenue from Contracts with Customers (ASC 606) provides for an exception to estimating the variable consideration for sales- and usage-based royalties related to the license of intellectual property, such that the sales- and usage-based royalty will be recognized in the period the underlying transaction occurs. The Company recognizes revenue from sales- and usage-based royalty revenue at the later of when the sale or usage occurs and the satisfaction or partial satisfaction of the performance obligation to which the royalty has been allocated. Changes in deferred revenue from contracts with customers were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 Balance at December 31 $ 7,460 ​ $ 5,998 Deferral of revenue 9,559 ​ 5,486 Recognition of deferred revenue (6,452) ​ (4,812) Balance at September 30 $ 10,567 ​ $ 6,672 ​ As of September 30, 2022, of the performance obligations not yet satisfied or partially satisfied, $9.0 million is expected to be recognized as revenue in the next 12 months, with the remainder amounts to initial and extended service-type warranties and research services, as well as $0.5 million related to undelivered licenses of intellectual property for a diagnostics company (see Note 5). Costs to obtain a contract The Company’s sales commissions are generally based on bookings of the Company. The Company has determined that certain commissions paid under its sales incentive programs meet the requirements to be capitalized as they are incremental and would not have occurred absent a customer contract. The change in the balance of costs to obtain a contract are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 Balance at December 31 $ 440 ​ $ 248 Deferral of costs to obtain a contract 1,182 ​ 558 Recognition of costs to obtain a contract (914) ​ (435) Balance at September 30 $ 708 ​ $ 371 ​ The Company has classified the balance of capitalized costs to obtain a contract as a component of prepaid expenses and other current assets and classifies the expense as a component of cost of goods sold and selling, general, and administrative expense over the estimated life of the contract. The Company considers potential impairment in these amounts each period. ASC 606 provides entities with certain practical expedients and accounting policy elections to minimize the cost and burden of adoption. The Company does not disclose the value of unsatisfied performance obligations for (i) contracts with original expected length of one year or less and (ii) contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed. The Company will exclude from its transaction price any amounts collected from customers related to sales and other similar taxes. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. The Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of September 30, 2022 and 2021, respectively. The Company has elected to account for the shipping and handling as an activity to fulfill the promise to transfer the product, and therefore will not evaluate whether shipping and handling activities are promised services to its customers. Grant revenue ​ The Company recognizes grant revenue as the Company performs services under the arrangement when the funding is committed. Revenues and related research and development expenses are presented gross in the consolidated statements of operations as the Company has determined it is the primary obligor under the arrangement relative to the research and development services. Accounting for grants does not fall under ASC 606, as the grantor will not benefit directly from the Company’s expansion or product development. As there is no authoritative guidance under U.S. GAAP on accounting for grants to for-profit business entities from government entities, the Company has accounted for grants obtained with the National Institute of Health (NIH) under its Rapid Acceleration of Diagnostics (RADx) program by analogy to International Accounting Standards Topic 20, Accounting for Government Grants and Disclosure of Government Assistance The Company accounts for grants from the Alzheimer’s Drug Discovery Foundation (ADDF) under ASC Topic 958, Not-for-Profit Entities Under IAS 20, grants related to assets shall be presented in the consolidated balance sheets either by recognizing the grant as deferred income (which is recognized in the consolidated statements of operations on a systematic basis over the useful life of the asset), or by deducting the grant in calculating the carrying amount of the asset (which is recognized in the consolidated statements of operations over the life of the depreciable asset as a reduced depreciation expense). Both methods are acceptable under IAS 20. The Company has elected to record grants related to assets as a deduction in calculating the carrying value of the asset. Under IAS 20, grants related to income are presented as part of the consolidated statements of operations, either separately or under a general heading. Both methods are acceptable under IAS 20. The Company has elected to record grants related to income separately on the consolidated statements of operations as grant revenue. The related expenses are recorded within operating expenses. Under ASC 958, grants related to income are presented as part of the consolidated statements of operations, either separately or under a general heading. Both methods are acceptable under ASC 958. The Company has elected to record grants related to income separately on the consolidated statements of operations as grant revenue. The related expenses are recorded within operating expenses. RADx grant On September 29, 2020, the Company entered into a contract with RADx (the RADx Grant), which had a total award value of $18.2 million and accelerated the continued development, scale-up, and deployment of the novel SARS-CoV-2 antigen detection test using the Company’s Simoa technology. The RADx Grant provided funding to expand assay kit manufacturing capacity and commercial deployment readiness. Release of the $18.2 million of funding under the RADx Grant was based on the achievement of certain milestones. Contract funding was subject to achievement of these pre-defined milestones and the contract period ran through September 2021, with one milestone extending to May 31, 2022. The Company has received the full $18.2 million under the RADx Grant and the Company has no future obligations under the RADx Grant. During the three and nine months ended September 30, 2022, the Company recognized no grant revenue and incurred no research and development expense related to the RADx Grant. During the three months ended September 30, 2021, the Company recognized $1.0 million in grant revenue and incurred $0.5 million in research and development expense related to the RADx grant. During the nine months ended September 30, 2021, the Company recognized $4.2 million in grant revenue and incurred $3.4 million in research and development expense related to the RADx Grant. The RADx Grant contains both monetary amounts granted related to assets and monetary amounts granted related to income, which are grants other than those related to assets. The grants related to assets are for the expansion and increase of manufacturing capacity. The grants related to income are for additional research and development, as well as other non-asset related scale up costs. The following table summarizes the cumulative activity under the RADx Grant (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 December 31, 2021 Grant revenue from research and development activities $ 9,576 ​ $ 9,576 Proceeds used for assets ​ 8,624 ​ ​ 8,104 Deferred proceeds for assets ​ — ​ ​ — Deferred grant revenue ​ — ​ ​ — Total recognized $ 18,200 ​ $ 17,680 ​ ​ ​ ​ ​ ​ Recognized $ 18,200 ​ $ 17,680 Amount accrued ​ — ​ ​ — Total cash received $ 18,200 ​ $ 17,680 ​ ​ ​ ​ ​ ​ Proceeds received $ 18,200 ​ $ 17,680 Proceeds reasonably assured ​ — ​ ​ 520 Total RADx Grant amount $ 18,200 ​ $ 18,200 ​ ADDF ​ On March 24, 2022, the Company entered into a contract with the Alzheimer’s Drug Discovery Foundation (ADDF) (the ADDF Grant). ADDF is a charitable venture philanthropy entity that has granted the Company funding in support of certain activities for the development of an in vitro diagnostic (IVD) test for early detection of Alzheimer's disease. The ADDF Grant, which has a total funding value of $2.3 million, restricts the Company’s use of the granted funds to be used solely for activities related to the Alzheimer’s diagnostic test development project. Contract funding is subject to achievement of these pre-defined milestones and the contract period runs through June 2024. The Company recognizes revenue over time as the related services are performed. As of September 30, 2022, the Company had received $1.3 million of the total funding value of $2.3 million under the ADDF Grant. During the three months ended September 30, 2022, the Company recognized $0.3 million in grant revenue and incurred $0.3 million in research and development expense related to the ADDF Grant. During the nine months ended September 30, 2022, the Company recognized $0.4 million in grant revenue and incurred $0.4 million in research and development expense related to the ADDF Grant.

Allowance for Credit Losses

Allowance for Credit Losses	9 Months Ended
	Sep. 30, 2022
Allowance for Credit Losses
Allowance for Credit Losses	4. Allowance for credit losses The Company is exposed to credit losses primarily through sales of products and services. The Company’s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions, and a review of the current status of customers’ trade accounts receivable. Due to the short-term nature of such receivables, the estimated accounts receivable that may not be collected is based on aging of the accounts receivable balances. Customers are assessed for credit worthiness upfront through a credit review, which includes assessment based on the Company’s analysis of customers’ financial statements when a credit rating is not available. The Company evaluates contract terms and conditions, country, and political risk, and may require prepayment to mitigate risk of loss. Specific allowance amounts are established to record the appropriate provision for customers that have a higher probability of default. The Company monitors changes to the receivables balance on a timely basis, and balances are written off as they are determined to be uncollectable after all collection efforts have been exhausted. Activity related to the allowance for credit losses was as follows (in thousands): ​ ​ 2022 ​ 2021 Balance at January 1 $ 419 ​ $ 370 Provision for credit losses, net of recoveries ​ 102 ​ ​ 275 Balance at September 30 $ 521 ​ $ 645 ​

Collaboration and license arran

Collaboration and license arrangements	9 Months Ended
	Sep. 30, 2022
Collaboration and license arrangements
Collaboration and license arrangements	5. Collaboration and license arrangements The Company has entered into certain licenses with other companies for use of the Company’s technology. These licenses have royalty components which the Company earns and recognizes as collaboration and license revenue throughout the year. At both September 30, 2022 and December 31, 2021, the Company had $0.5 million of deferred revenue related to ongoing negotiations with a diagnostics company. ​ Abbott Laboratories ​ On September 29, 2020, the Company entered into a Non-Exclusive License Agreement (the Abbott License Agreement) with Abbott Laboratories (Abbott). Under the terms of the Abbott License Agreement, the Company granted Abbott a non-exclusive, worldwide, royalty-bearing license, without the right to sublicense, under the Company’s bead-based single molecule detection patents (Licensed Patents) in the field of in vitro The Abbott License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. The Abbott License Agreement became effective upon signing and will continue until expiration of the last-to-expire Licensed Patent, or the agreement is earlier terminated. Under the terms of the Abbott License Agreement, the Company and Abbott each have the right to terminate the agreement for uncured material breach by, or insolvency of, the other party. Abbott may also terminate the Abbott License Agreement at any time without cause upon 60 days’ notice. ​ During the three and nine months ended September 30, 2022 and 2021, the Company did not recognize any revenue under the Abbott License Agreement.

Net loss per share

Net loss per share	9 Months Ended
	Sep. 30, 2022
Net loss per share
Net loss per share	6 The following common share equivalents have been excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 ​ 2022 2021 Stock options 2,503,077 2,244,295 ​ ​ 2,423,296 2,244,295 Unvested restricted stock and stock units 902,220 607,118 ​ ​ 807,360 607,118 ​

Fair value of financial instrum

Fair value of financial instruments	9 Months Ended
	Sep. 30, 2022
Fair value of financial instruments
Fair value of financial instruments	7. Fair value of financial instruments Fair value measurements are as follows (in thousands): September 30, 2022 Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Financial assets ​ ​ ​ ​ ​ Cash equivalents - money market funds $ 333,716 $ 333,716 ​ $ — $ — ​ December 31, 2021 Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Financial assets ​ ​ ​ ​ ​ Cash equivalents - money market funds $ 332,093 $ 332,093 ​ $ — $ — ​

Inventory

Inventory	9 Months Ended
	Sep. 30, 2022
Inventory
Inventory	8. Inventory Inventory consists of the following (in thousands): ​ September 30, 2022 ​ December 31, 2021 Raw materials $ 7,467 ​ $ 7,892 Work in process 3,485 ​ 4,923 Finished goods 7,284 ​ 9,375 Total net inventory $ 18,236 ​ $ 22,190 ​

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2022
Goodwill.
Goodwill	9. Goodwill During the third quarter of 2022, the Company identified certain indicators of impairment, including the significant decline in the Company’s stock price, actions taken under the Restructuring Plan and the reduction of forecasted sales and profitability. As a result, the Company performed an interim goodwill impairment test. It was determined that the Company’s goodwill was impaired as the carrying amount of the Company’s sole reporting unit exceeded the estimated fair value. The Company concluded that the entire goodwill balance was impaired and recognized a non-cash impairment charge during the third quarter of 2022. The changes in the carrying value of goodwill are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 ​ Balance at January 1 $ 9,632 ​ $ 10,460 ​ Impairment losses ​ (8,220) ​ ​ — ​ Foreign exchange adjustments ​ (1,412) ​ ​ (557) ​ Balance at September 30 $ — ​ $ 9,903 ​ ​

Other accrued expenses

Other accrued expenses	9 Months Ended
	Sep. 30, 2022
Other accrued expenses
Other accrued expenses	10. Other accrued expenses ​ Other accrued expenses consist of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 ​ December 31, 2021 Royalties $ 734 ​ $ 1,250 Professional and outside services 1,219 ​ 2,126 Tax liabilities ​ 787 ​ ​ 430 Other 3,211 ​ 2,680 Total accrued expenses $ 5,951 ​ $ 6,486 ​

Stock-based compensation

Stock-based compensation	9 Months Ended
	Sep. 30, 2022
Stock-based compensation
Stock-based compensation	​ 11. Stock-based compensation Stock-based compensation expense for all stock awards consists of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 2022 2021 Cost of product revenue $ 199 ​ $ 96 ​ $ 424 ​ $ 282 Cost of service and other revenue 159 ​ 115 ​ 530 ​ 347 Research and development 320 ​ 440 ​ 1,200 ​ 1,248 Selling, general, and administrative 2,088 ​ 3,357 ​ 9,625 ​ 9,167 Total stock-based compensation $ 2,766 ​ $ 4,008 ​ $ 11,779 ​ $ 11,044 ​ As of September 30, 2022, there was $37.1 million of total unrecognized compensation cost related to unvested restricted stock units and stock options, which is expected to be recognized over the remaining weighted-average vesting period of 3.1 years.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases
Leases	12. Leases ​ The Company is a lessee under leases of offices, lab spaces, and certain office equipment. Some of the Company’s leases include options to extend the lease, and these options are included in the lease term to the extent they are reasonably certain to be exercised. On January 28, 2022, the Company executed a lease for 85,800 square feet of office and laboratory space in Bedford, Massachusetts. The lease commencement date was February 1, 2022, when the Company gained access to the underlying facilities. The Company has negotiated a tenant improvement allowance with the landlord which will offset a portion of the Company’s construction costs. The Company has assessed whether improvements made to the premises are landlord-owned or company-owned, with payments made by the Company for landlord-owned assets accounted for as lease incentives. The initial term of the lease’s payment schedule is eight years and nine months beginning on May 1, 2022. The Company has the option to extend the lease for two additional five-year periods. As part of the Restructuring Plan, the Company decided not to utilize these facilities as part of its own operations. During the third quarter of 2022, the Company recorded an impairment of $7.7 million related to the Bedford facilities, including $5.5 million relating to the right-of-use assets and $2.2 million associated with property and equipment. ​ The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, Operating leases ​ 2022 ​ 2021 ​ 2022 ​ 2021 Lease costs (1) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ $ 1,500 ​ $ 663 ​ $ 3,733 ​ $ 1,997 Total lease cost ​ $ 1,500 ​ $ 663 ​ $ 3,733 ​ $ 1,997 ​ (1) Short-term lease costs and variable lease costs incurred by the Company for the three and nine months ended September 30, 2022 were not material. ​ Supplemental balance sheet and cash flow information was as follows (amounts in thousands): ​ A ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ Supplemental balance sheet information: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term ​ ​ 8.2 years ​ 8.9 years ​ 8.2 years ​ 8.9 years Weighted average discount rate ​ ​ 7.2% ​ ​ 9.7% ​ ​ 7.2% ​ ​ 9.7% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental cash flow information: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows used for operating leases ​ $ 1,398 ​ $ 849 ​ $ 2,792 ​ $ 2,532 ​ ​ Future minimum commitments under the Company’s operating leases were as follows (in thousands): ​ ​ ​ ​ ​ Twelve months ending September 30, ​ ​ 2023 ​ $ 6,356 2024 ​ ​ 6,992 2025 ​ ​ 7,173 2026 ​ ​ 7,328 2027 ​ ​ 7,561 Thereafter ​ ​ 25,603 Total lease payments ​ ​ 61,013 Less: imputed interest ​ ​ 18,050 Total operating lease liabilities ​ $ 42,963 ​

Income taxes

Income taxes	9 Months Ended
	Sep. 30, 2022
Income taxes
Income taxes	13. Income taxes The Company recorded provisions for income taxes of $72 thousand and $33 thousand for the three months ended September 30, 2022 and 2021, respectively, and provisions of $10 thousand and $32 thousand for the nine months ended September 30, 2022 and 2021, respectively. The Company's effective tax rates were 0.21% for both the three months ended September 30, 2022 and 2021, respectively, 0.01% and 0.09% for the nine months ended September 30, 2022 and 2021, respectively. The income tax provisions and the effective tax rates are primarily driven by state and international taxes. ​ The Company maintains a valuation allowance on the majority of its deferred tax assets, and it has concluded that it is more likely than not that the deferred assets will not be utilized. ​

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and contingencies
Commitments and contingencies	14. Commitments and contingencies Legal contingencies The Company is subject to claims in the ordinary course of business; however, the Company is not currently a party to any pending or threatened litigation, the outcome of which would be expected to have a material adverse effect on its financial condition or the results of its operations. The Company accrues for contingent liabilities to the extent that the liability is probable and estimable.

Related party transactions

Related party transactions	9 Months Ended
	Sep. 30, 2022
Related party transactions
Related party transactions	15. Related party transactions ​ One of the Company’s Directors is affiliated with Harvard University and Mass General Brigham. Revenue recorded from sales to Harvard University and its affiliates and to Mass General Brigham and its affiliates totaled $0.2 million and $0.5 million for the three and nine months ended September 30, 2022, respectively, and $0.2 million for both the three and nine months ended September 30, 2021, respectively. The Company recorded cost of goods sold of $0.1 million for the three months ended September 30, 2022 related to Harvard University and its affiliates and to Mass General Brigham and its affiliates. The Company had $0.2 million in accounts receivable from Harvard University and its affiliates and Mass General Brigham and its affiliates at both September 30, 2022 and December 31, 2021. Deferred revenue from Harvard University and its affiliates and Mass General Brigham and its affiliates was $0.1 million at both September 30, 2022 and December 31, 2021. ​ On May 26, 2022, the Company entered into an agreement with UltraDx Limited (the UltraDx Agreement), a new company formed by ARCH Venture Partners (ARCH). Under the UltraDx Agreement, the Company will supply HD-X instruments (both fully assembled and disassembled) as well as assays and assay components to UltraDx, and UltraDx has the non-exclusive right to seek Chinese regulatory approval of and to commercialize the HD-X instrument and related assays in the Chinese neurological in vitro diagnostic market. The Company has determined that UltraDx is a related party because one of the Company’s directors is affiliated with ARCH and UltraDx. Under the terms of the UltraDx Agreement, the Company shipped a total of ten fully assembled and disassembled HD-X instruments to UltraDx on June 30, 2022 at a purchase price of approximately $1.9 million. Because UltraDx was formed during the second quarter of 2022, the Company recognized revenue on these shipments upon receipt of payment during the three months ended September 30, 2022. ​

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2022
Accumulated Other Comprehensive Loss.
Accumulated Other Comprehensive Loss	16. Accumulated other comprehensive loss ​ The following shows the changes in the components of accumulated other comprehensive loss (in thousands): ​ ​ ​ ​ ​ ​ ​ Cumulative Translation Adjustment ​ Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2020 $ 2,434 ​ $ 2,434 Foreign currency translation adjustments ​ (1,993) ​ ​ (1,993) Balance at December 31, 2021 $ 441 ​ $ 441 Foreign currency translation adjustments ​ (3,440) ​ ​ (3,440) Balance at September 30, 2022 $ (2,999) ​ $ (2,999) ​

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2022
Restructuring
Restructuring	17. Restructuring Following a strategic review and assessment of the Company’s operations and cost structure, on August 8, 2022, the Company announced a plan of restructuring and strategic re-alignment (the Restructuring Plan). As part of the Restructuring Plan, the Company began an assay redevelopment program with the ultimate objective of improving its ability to manufacture and deliver high-quality assays at scale. The Restructuring Plan aligns the Company’s investments to best serve the needs of its customers, focuses the Company’s innovation efforts on key platforms and provides a foundation for the Company’s entry into translational pharma and clinical markets, which it believes will be required to access new growth categories. In accordance with the Restructuring Plan, the Company implemented a workforce reduction, which was substantially completed by the end of the third quarter of 2022. The Company recorded charges in the three months ended September 30, 2022, consisting of one-time termination benefits for employee severance, benefits and related costs, all of which were cash expenditures. The following shows the number of positions by function and by location eliminated in connection with the Restructuring Plan: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ North America ​ EMEA ​ Asia Pacific ​ Total Cost of goods sold 21 ​ — ​ — ​ 21 Research and development 34 ​ 1 ​ — ​ 35 Selling, general and administrative 50 ​ 9 ​ 4 ​ 63 Total headcount 105 ​ 10 ​ 4 ​ 119 ​ As part of the Restructuring Plan, the Company also performed an assessment of impairment for long-lived assets, including right-of-use assets, and recorded an impairment charge of $8.7 million. The impairment expense includes $7.7 million associated with the right-of-use and property and equipment at the Bedford facilities (see Note 12). Additionally, the Company recorded an impairment charge of $1.0 million for software costs related to projects that have been rationalized as part of the Restructuring Plan. The following presents a rollforward of the restructuring reserve and provision activity (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Severance and Employee Benefit Costs ​ Other Restructuring Charges ​ Total Balance at June 30, 2022 $ — ​ $ — ​ $ — Charges ​ 3,325 ​ ​ 101 ​ ​ 3,426 Cash payments ​ (2,995) ​ ​ (101) ​ ​ (3,096) Foreign exchange ​ 7 ​ ​ — ​ ​ 7 Balance at September 30, 2022 $ 337 ​ $ — ​ $ 337 ​

Significant accounting polici_2

Significant accounting policies (Policies)	9 Months Ended
	Sep. 30, 2022
Significant accounting policies
Goodwill	Goodwill Goodwill represents the excess of the cost of acquired businesses over the fair value of identifiable net assets assumed in a business combination. Goodwill is assessed for impairment at least annually, on a reporting unit basis, or more frequently when events and circumstances occur indicating that the recorded goodwill may be impaired. Reporting units are one level below the business segment level but can be combined when reporting units within the same segment have similar economic characteristics. The Company operates within a single
Long-Lived Assets	Long-lived assets The Company accounts for long-lived assets including property and equipment and long-lived amortizable intangible assets in accordance with ASC Topic No. 360, Property, Plant and Equipment, .
Restructuring	Restructuring The Company records charges associated with approved restructuring plans to reorganize operations, to improve the efficiency of business processes, or to remove redundant headcount. Restructuring charges can include severance costs to eliminate a specific number of employees, associated legal fees and contract cancellation costs. The Company records restructuring charges when they are probable and estimable. The Company accrues for severance and other employee separation costs under these plans when employees accept the separation offers, and the amounts can be reasonably estimated. The Company implemented a restructuring plan (as defined herein) during the three months ended September 30, 2022 details of which are discussed in Note 17.

Revenue recognition (Tables)

Revenue recognition (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue recognition
Schedule of disaggregated revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, 2022 Three Months Ended September 30, 2021 ​ North America EMEA Asia Pacific Total ​ North America EMEA Asia Pacific Total Product revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Instruments $ 2,964 ​ ​ 3,115 ​ ​ 1,684 ​ $ 7,763 ​ $ 3,492 ​ $ 1,644 ​ $ 1,338 $ 6,474 Consumable and other products ​ 6,262 ​ ​ 2,840 ​ ​ 828 ​ ​ 9,930 ​ ​ 8,915 ​ ​ 4,483 ​ ​ 790 ​ 14,188 Total $ 9,226 ​ ​ 5,955 ​ ​ 2,512 ​ $ 17,693 ​ $ 12,407 $ 6,127 $ 2,128 $ 20,662 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Service and other revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Service-type warranties $ 1,454 ​ $ 703 ​ $ 125 ​ $ 2,282 ​ $ 1,112 ​ $ 556 ​ $ 66 $ 1,734 Research services ​ 5,246 ​ ​ 305 ​ ​ 44 ​ 5,595 ​ ​ 2,998 ​ ​ 604 ​ ​ 50 ​ 3,652 Other services ​ 315 ​ ​ 142 ​ ​ 36 ​ ​ 493 ​ ​ 465 ​ ​ 47 ​ ​ — ​ 512 Total $ 7,015 ​ $ 1,150 ​ $ 205 ​ $ 8,370 ​ $ 4,575 ​ $ 1,207 ​ $ 116 ​ $ 5,898 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Collaboration and license revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Collaboration and license revenue $ 136 ​ $ 165 ​ $ — ​ $ 301 ​ $ 73 ​ $ 47 ​ $ — ​ $ 120 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, 2022 Nine Months Ended September 30, 2021 ​ North America EMEA Asia Pacific Total ​ North America EMEA Asia Pacific Total Product revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Instruments $ 7,602 ​ $ 7,288 ​ $ 4,699 ​ $ 19,589 ​ $ 9,370 ​ $ 6,107 ​ $ 3,796 ​ $ 19,273 Consumable and other products ​ 19,814 ​ ​ 10,854 ​ ​ 2,877 ​ ​ 33,545 ​ ​ 24,638 ​ ​ 11,227 ​ ​ 2,448 ​ ​ 38,313 Total $ 27,416 $ 18,142 $ 7,576 $ 53,134 ​ $ 34,008 $ 17,334 $ 6,244 $ 57,586 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Service and other revenues ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Service-type warranties $ 4,057 ​ $ 2,050 ​ $ 341 ​ $ 6,448 ​ $ 3,181 ​ $ 1,452 ​ $ 179 ​ $ 4,812 Research services ​ 16,853 ​ ​ 752 ​ ​ 65 ​ 17,670 ​ ​ 9,285 ​ ​ 2,095 ​ ​ 89 ​ 11,469 Other services ​ 916 ​ ​ 590 ​ ​ 104 ​ ​ 1,610 ​ ​ 1,271 ​ ​ 403 ​ ​ — ​ ​ 1,674 Total $ 21,826 ​ $ 3,392 ​ $ 510 ​ $ 25,728 ​ $ 13,737 ​ $ 3,950 ​ $ 268 ​ $ 17,955 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Collaboration and license revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Collaboration and license revenue $ 179 ​ $ 248 ​ $ 52 ​ $ 479 ​ $ 301 ​ $ 185 ​ $ — ​ $ 486 ​
Schedule of changes in deferred revenue from contracts with customers	Changes in deferred revenue from contracts with customers were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 Balance at December 31 $ 7,460 ​ $ 5,998 Deferral of revenue 9,559 ​ 5,486 Recognition of deferred revenue (6,452) ​ (4,812) Balance at September 30 $ 10,567 ​ $ 6,672
Schedule of costs to obtain a contract	​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 Balance at December 31 $ 440 ​ $ 248 Deferral of costs to obtain a contract 1,182 ​ 558 Recognition of costs to obtain a contract (914) ​ (435) Balance at September 30 $ 708 ​ $ 371 ​
Schedule of summary of the activity under WP2	The following table summarizes the cumulative activity under the RADx Grant (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 December 31, 2021 Grant revenue from research and development activities $ 9,576 ​ $ 9,576 Proceeds used for assets ​ 8,624 ​ ​ 8,104 Deferred proceeds for assets ​ — ​ ​ — Deferred grant revenue ​ — ​ ​ — Total recognized $ 18,200 ​ $ 17,680 ​ ​ ​ ​ ​ ​ Recognized $ 18,200 ​ $ 17,680 Amount accrued ​ — ​ ​ — Total cash received $ 18,200 ​ $ 17,680 ​ ​ ​ ​ ​ ​ Proceeds received $ 18,200 ​ $ 17,680 Proceeds reasonably assured ​ — ​ ​ 520 Total RADx Grant amount $ 18,200 ​ $ 18,200

Allowance for Credit Losses (Ta

Allowance for Credit Losses (Tables)	9 Months Ended
	Sep. 30, 2022
Allowance for Credit Losses
Schedule of the allowance for credit losses	​ ​ 2022 ​ 2021 Balance at January 1 $ 419 ​ $ 370 Provision for credit losses, net of recoveries ​ 102 ​ ​ 275 Balance at September 30 $ 521 ​ $ 645

Net loss per share (Tables)

Net loss per share (Tables)	9 Months Ended
	Sep. 30, 2022
Net loss per share
Schedule of common share equivalents have been excluded from the calculation of diluted net loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 ​ 2022 2021 Stock options 2,503,077 2,244,295 ​ ​ 2,423,296 2,244,295 Unvested restricted stock and stock units 902,220 607,118 ​ ​ 807,360 607,118

Fair value of financial instr_2

Fair value of financial instruments (Tables)	9 Months Ended
	Sep. 30, 2022
Fair value of financial instruments
Schedule of fair value measurements	Fair value measurements are as follows (in thousands): September 30, 2022 Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Financial assets ​ ​ ​ ​ ​ Cash equivalents - money market funds $ 333,716 $ 333,716 ​ $ — $ — ​ December 31, 2021 Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Financial assets ​ ​ ​ ​ ​ Cash equivalents - money market funds $ 332,093 $ 332,093 ​ $ — $ —

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory
Summary of inventory	Inventory consists of the following (in thousands): ​ September 30, 2022 ​ December 31, 2021 Raw materials $ 7,467 ​ $ 7,892 Work in process 3,485 ​ 4,923 Finished goods 7,284 ​ 9,375 Total net inventory $ 18,236 ​ $ 22,190

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill.
Changes in the carrying value of goodwill	The changes in the carrying value of goodwill are as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ 2022 ​ 2021 ​ Balance at January 1 $ 9,632 ​ $ 10,460 ​ Impairment losses ​ (8,220) ​ ​ — ​ Foreign exchange adjustments ​ (1,412) ​ ​ (557) ​ Balance at September 30 $ — ​ $ 9,903 ​

Other accrued expenses (Tables)

Other accrued expenses (Tables)	9 Months Ended
	Sep. 30, 2022
Other accrued expenses
Summary of other accrued expenses	Other accrued expenses consist of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ September 30, 2022 ​ December 31, 2021 Royalties $ 734 ​ $ 1,250 Professional and outside services 1,219 ​ 2,126 Tax liabilities ​ 787 ​ ​ 430 Other 3,211 ​ 2,680 Total accrued expenses $ 5,951 ​ $ 6,486

Stock-based compensation (Table

Stock-based compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Stock-based compensation
Summary of share-based compensation expense for all stock awards	Stock-based compensation expense for all stock awards consists of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ 2022 2021 2022 2021 Cost of product revenue $ 199 ​ $ 96 ​ $ 424 ​ $ 282 Cost of service and other revenue 159 ​ 115 ​ 530 ​ 347 Research and development 320 ​ 440 ​ 1,200 ​ 1,248 Selling, general, and administrative 2,088 ​ 3,357 ​ 9,625 ​ 9,167 Total stock-based compensation $ 2,766 ​ $ 4,008 ​ $ 11,779 ​ $ 11,044

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Leases
Summary of the lease costs recognized under ASC 842	The components of lease expense were as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, Operating leases ​ 2022 ​ 2021 ​ 2022 ​ 2021 Lease costs (1) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating lease costs ​ $ 1,500 ​ $ 663 ​ $ 3,733 ​ $ 1,997 Total lease cost ​ $ 1,500 ​ $ 663 ​ $ 3,733 ​ $ 1,997 ​ (1) Short-term lease costs and variable lease costs incurred by the Company for the three and nine months ended September 30, 2022 were not material. ​ Supplemental balance sheet and cash flow information was as follows (amounts in thousands): ​ A ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, ​ ​ ​ 2022 ​ 2021 ​ 2022 ​ 2021 ​ Supplemental balance sheet information: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average remaining lease term ​ ​ 8.2 years ​ 8.9 years ​ 8.2 years ​ 8.9 years Weighted average discount rate ​ ​ 7.2% ​ ​ 9.7% ​ ​ 7.2% ​ ​ 9.7% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Supplemental cash flow information: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating cash flows used for operating leases ​ $ 1,398 ​ $ 849 ​ $ 2,792 ​ $ 2,532 ​
Schedule of future minimum commitments under ASC 842	Future minimum commitments under the Company’s operating leases were as follows (in thousands): ​ ​ ​ ​ ​ Twelve months ending September 30, ​ ​ 2023 ​ $ 6,356 2024 ​ ​ 6,992 2025 ​ ​ 7,173 2026 ​ ​ 7,328 2027 ​ ​ 7,561 Thereafter ​ ​ 25,603 Total lease payments ​ ​ 61,013 Less: imputed interest ​ ​ 18,050 Total operating lease liabilities ​ $ 42,963

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2022
Accumulated Other Comprehensive Loss.
Schedule of Accumulated other comprehensive loss	The following shows the changes in the components of accumulated other comprehensive loss (in thousands): ​ ​ ​ ​ ​ ​ ​ Cumulative Translation Adjustment ​ Accumulated Other Comprehensive Income (Loss) Balance at December 31, 2020 $ 2,434 ​ $ 2,434 Foreign currency translation adjustments ​ (1,993) ​ ​ (1,993) Balance at December 31, 2021 $ 441 ​ $ 441 Foreign currency translation adjustments ​ (3,440) ​ ​ (3,440) Balance at September 30, 2022 $ (2,999) ​ $ (2,999)

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2022
Restructuring
Schedule of number of positions by function and by location eliminated by the Restructuring	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ North America ​ EMEA ​ Asia Pacific ​ Total Cost of goods sold 21 ​ — ​ — ​ 21 Research and development 34 ​ 1 ​ — ​ 35 Selling, general and administrative 50 ​ 9 ​ 4 ​ 63 Total headcount 105 ​ 10 ​ 4 ​ 119
Schedule of rollforward of the restructuring reserve and provision activity	The following presents a rollforward of the restructuring reserve and provision activity (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Severance and Employee Benefit Costs ​ Other Restructuring Charges ​ Total Balance at June 30, 2022 $ — ​ $ — ​ $ — Charges ​ 3,325 ​ ​ 101 ​ ​ 3,426 Cash payments ​ (2,995) ​ ​ (101) ​ ​ (3,096) Foreign exchange ​ 7 ​ ​ — ​ ​ 7 Balance at September 30, 2022 $ 337 ​ $ — ​ $ 337

Significant accounting polici_3

Significant accounting policies (Details)	9 Months Ended
	Sep. 30, 2022 segment item
Significant accounting policies
Number of reporting units | item	1
Number of operating segments | segment	1

Revenue recognition - Customers

Revenue recognition - Customers and service and other revenue (Details) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2022 USD ($) customer	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) customer	Sep. 30, 2021 USD ($)
Revenue recognition
Service type warranties term				1 year
Revenue	$ 26,646		$ 27,689	$ 79,698	$ 80,269
Accounts Receivable
Revenue recognition
Number Of Customers With High Percent Of Gross Accounts Receivable | customer	2			2
Customer Concentration Risk | Revenue
Revenue recognition
Number Of Customers With High Percent Of Total Revenue | customer	2			2
One customer | Accounts Receivable
Revenue recognition
Concentration Risk Percentage	13.40%			13.40%
One customer | Customer Concentration Risk | Revenue
Revenue recognition
Revenue as a percentage of total revenue	14.10%
Two customer | Accounts Receivable
Revenue recognition
Concentration Risk Percentage	10.10%			10.10%
Two customer | Customer Concentration Risk | Revenue
Revenue recognition
Revenue as a percentage of total revenue				11.10%
Product revenue
Revenue recognition
Revenue	$ 17,693		20,662	$ 53,134	57,586
Service and other revenue
Revenue recognition
Revenue	8,370		$ 5,898	25,728	$ 17,955
Collaboration agreement | Service and other revenue
Revenue recognition
Revenue	2,700			8,100
Collaboration agreement | Eli Lilly
Revenue recognition
Transaction price due	$ 10,900			10,900
Master collaboration agreement | Eli Lilly
Revenue recognition
Non-refundable up-front payment received		$ 5,000
Statement of works agreement | Eli Lilly
Revenue recognition
Collaborative arrangement payment received per quarter				$ 1,500
Minimum
Revenue recognition
Period of payment				30 days
Maximum
Revenue recognition
Period of payment				45 days

Revenue recognition - Disaggreg

Revenue recognition - Disaggregated revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue recognition
Total revenue	$ 26,646	$ 27,689	$ 79,698	$ 80,269
Product revenue
Revenue recognition
Total revenue	17,693	20,662	53,134	57,586
Service and other revenue
Revenue recognition
Total revenue	8,370	5,898	25,728	17,955
Collaboration and license revenue
Revenue recognition
Total revenue	$ 301	$ 120	$ 479	$ 486

Revenue recognition - Future pe

Revenue recognition - Future performance obligations (Details) $ in Millions	Sep. 30, 2022 USD ($)
Service-type warranties and research services
Transaction Price Allocated to Future Performance Obligations
Amount of transaction price allocated to performance obligations	$ 0
Undelivered licenses of intellectual property
Transaction Price Allocated to Future Performance Obligations
Amount of transaction price allocated to performance obligations	0.5
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Transaction Price Allocated to Future Performance Obligations
Amount of transaction price allocated to performance obligations	$ 9
Performance obligation satisfaction period	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Transaction Price Allocated to Future Performance Obligations
Amount of transaction price allocated to performance obligations	$ 0
Performance obligation satisfaction period	24 months

Revenue recognition - Practical

Revenue recognition - Practical expedients (Details)	9 Months Ended
	Sep. 30, 2022
Revenue recognition
Revenue, Practical Expedient, Financing Component [true false]	true
Revenue, Remaining Performance Obligation, Optional Exemption, Performance Obligation [true false]	true

Revenue recognition - Grant rev

Revenue recognition - Grant revenue (Details) - USD ($) $ in Thousands			3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 24, 2022	Sep. 29, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Total revenue			$ 26,646	$ 27,689	$ 79,698	$ 80,269
Research and Development Expense			6,631	6,807	20,290	20,244
Proceeds from RADx grant on assets purchased					520	7,019
RADx
Research and Development Expense			500
RADx WP2
Contract value		$ 18,200			18,200
Research and Development Expense					0	3,400
ADDF
Contract value	$ 2,300				2,300
Proceeds from RADx grant on assets purchased					1,300
Grant revenue
Total revenue			282	1,009	357	4,242
Grant revenue | RADx WP2
Total revenue			0		9,576		$ 9,576
Contract value					18,200		$ 18,200
Grant revenue | ADDF
Total revenue			$ 300		$ 400	$ 400
Research and Development Expense				$ 300

Revenue recognition - Summarize

Revenue recognition - Summarizes the activity under WP2 (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Revenue recognition
Total revenue		$ 26,646	$ 27,689	$ 79,698	$ 80,269
Grant revenue
Revenue recognition
Total revenue		282	$ 1,009	357	$ 4,242
RADx WP2
Revenue recognition
Total WP2 grant amount	$ 18,200			18,200
RADx WP2 | Grant revenue
Revenue recognition
Total revenue		$ 0		9,576		$ 9,576
Proceeds used for assets				8,624		8,104
Total recognized				18,200		17,680
Total cash received				18,200		17,680
Proceeds received				18,200		17,680
Proceeds reasonably assured						520
Total WP2 grant amount				$ 18,200		$ 18,200

Allowance for Credit Losses (De

Allowance for Credit Losses (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Allowance for Credit Losses
Beginning Balance	$ 419	$ 370	$ 370
Credit loss expense on accounts receivable	102	286	102	$ 275
Ending Balance	$ 521	$ 645	$ 419	$ 370

Collaboration and license arr_2

Collaboration and license arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Collaboration and license arrangements
Revenue	$ 26,646	$ 27,689	$ 79,698	$ 80,269
Deferred revenue	500		500		$ 500
Abbot license agreement
Collaboration and license arrangements
Initial license fee receivable			$ 10,000
Number of days notice to terminate agreement			60 days
Collaboration and license revenue
Collaboration and license arrangements
Revenue	$ 301	$ 120	$ 479	$ 486

Net loss per share - Common sha

Net loss per share - Common share equivalents have been excluded from the calculation of diluted net loss per share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock options
Net loss per share
Number of common share equivalents excluded in the calculation of diluted net loss per share	2,503,077	2,244,295	2,423,296	2,244,295
Unvested restricted stock and stock units
Net loss per share
Number of common share equivalents excluded in the calculation of diluted net loss per share	902,220	607,118	807,360	607,118

Fair value of financial instr_3

Fair value of financial instruments (Details) - Money market funds - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash equivalents	$ 333,716	$ 332,093
Level 1
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]
Cash equivalents	$ 333,716	$ 332,093

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory
Raw Materials	$ 7,467	$ 7,892
Work in process	3,485	4,923
Finished goods	7,284	9,375
Total net inventory	$ 18,236	$ 22,190

Goodwill (Details)

Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Changes in the carrying value of goodwill
Balance as of beginning of period		$ 9,632	$ 10,460
Impairment losses	$ (8,220)	(8,220)
Foreign exchange adjustments		$ (1,412)	(557)
Balance as of end of period			$ 9,903

Other accrued expenses (Details

Other accrued expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Other accrued expenses
Royalties	$ 734	$ 1,250
Professional and outside services	1,219	2,126
Tax liabilities	787	430
Other	3,211	2,680
Total accrued expenses	$ 5,951	$ 6,486

Stock-based compensation - Shar

Stock-based compensation - Share-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock-based compensation
Share-based compensation expense	$ 2,766	$ 4,008	$ 11,779	$ 11,044
Cost of product revenue
Stock-based compensation
Share-based compensation expense	199	96	424	282
Cost of service and other revenue
Stock-based compensation
Share-based compensation expense	159	115	530	347
Research and development
Stock-based compensation
Share-based compensation expense	320	440	1,200	1,248
Selling, general, and administrative
Stock-based compensation
Share-based compensation expense	2,088	$ 3,357	9,625	$ 9,167
Restricted stock units and stock options
Stock-based compensation
Total unrecognized compensation cost related to unvested stock awards	$ 37,100		$ 37,100
Period of recognition of unrecognized compensation cost			3 years 1 month 6 days

Leases (Details)

Leases (Details)		3 Months Ended
	Feb. 01, 2022 item	Sep. 30, 2022 USD ($)	Jan. 28, 2022 USD ($)	Dec. 31, 2021 USD ($)
Leases
Impairment related to restructuring		$ 7,700,000
Right-of-use assets		27,165,000		$ 11,491,000
Office and Laboratory Space in Bedford, Massachusetts
Leases
Square footage of office and laboratory space			85,800
Term of operating lease	8 years 9 months
Lease agreement number of options to extend | item	2
Lease agreement lease extension term	5 years
Right-of-use assets		5,500,000
Impairment Property And Equipment		$ 2,200,000

Leases - Lease costs recognized

Leases - Lease costs recognized (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Lease Costs
Operating lease costs	$ 1,500	$ 663	$ 3,733	$ 1,997
Total lease cost	$ 1,500	$ 663	$ 3,733	$ 1,997
Weighted average remaining lease term	8 years 2 months 12 days	8 years 10 months 24 days	8 years 2 months 12 days	8 years 10 months 24 days
Weighted average discount rate	7.20%	9.70%	7.20%	9.70%
Operating cash flows used for operating leases	$ 1,398	$ 849	$ 2,792	$ 2,532

Leases - Future minimum commitm

Leases - Future minimum commitments (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Leases
2023	$ 6,356
2024	6,992
2025	7,173
2026	7,328
2027	7,561
Thereafter	25,603
Total lease payments	61,013
Less: imputed interest	18,050
Total operating lease liabilities	$ 42,963

Income taxes (Details)

Income taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income taxes
Income Tax Expense (Benefit)	$ 72	$ 33	$ 10	$ 32
Effective Income Tax Rate Reconciliation, Percent	(0.21%)	0.01%		(0.09%)

Related party transactions (Det

Related party transactions (Details) $ in Millions		3 Months Ended		9 Months Ended
	Jun. 30, 2022 USD ($) item	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Harvard University
Related party transactions
Related party revenue		$ 0.2	$ 0.2	$ 0.5	$ 0.2
Accounts receivable, related parties		0.2		0.2		$ 0.2
Deferred revenue from related parties		0.1		$ 0.1		$ 0.1
Cost of revenue, related party activity		$ 0.1
UltraDx
Related party transactions
Purchase price	$ 1.9
Number Of Manufacturing Instruments | item	10

Accumulated other comprehensi_3

Accumulated other comprehensive loss (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Accumulated other comprehensive loss
Current period accumulated other comprehensive loss	$ (796)	$ (527)	$ (3,440)	$ (1,383)
Cumulative translation adjustment
Accumulated other comprehensive loss
Beginning balance			441	2,434	$ 2,434
Current period accumulated other comprehensive loss			(3,440)		(1,993)
Ending Balance	(2,999)		(2,999)		441
Accumulated other comprehensive income (loss)
Accumulated other comprehensive loss
Beginning balance			441	2,434	2,434
Current period accumulated other comprehensive loss	(796)	$ (527)	(3,440)	$ (1,383)	(1,993)
Ending Balance	$ (2,999)		$ (2,999)		$ 441

Restructuring (Details)

Restructuring (Details) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($) position
Restructuring
Total headcount		119
Impairment of long-lived assets | $	$ 8,695	$ 8,695
Property And Equipment [Member]
Restructuring
Impairment of long-lived assets | $		7,700
Software and Software Development Costs [Member]
Restructuring
Impairment of long-lived assets | $		$ 1,000
NA
Restructuring
Total headcount		105
EMEA
Restructuring
Total headcount		10
Asia Pacific
Restructuring
Total headcount		4
Cost of goods sold
Restructuring
Total headcount		21
Cost of goods sold | NA
Restructuring
Total headcount		21
Research and development
Restructuring
Total headcount		35
Research and development | NA
Restructuring
Total headcount		34
Research and development | EMEA
Restructuring
Total headcount		1
Selling, general and administrative
Restructuring
Total headcount		63
Selling, general and administrative | NA
Restructuring
Total headcount		50
Selling, general and administrative | EMEA
Restructuring
Total headcount		9
Selling, general and administrative | Asia Pacific
Restructuring
Total headcount		4

Restructuring - Roll forward (D

Restructuring - Roll forward (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Restructuring
Charges	$ 3,426	$ 3,426
Cash payments	(3,096)
Foreign exchange	7
Balance at End of period	337	337
Severance and Employee Benefit Costs
Restructuring
Charges	3,325
Cash payments	(2,995)
Foreign exchange	7
Balance at End of period	337	$ 337
Other Restructuring Charges
Restructuring
Charges	101
Cash payments	$ (101)